Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)
26 October 2017 - 3:00AM
Press release
25 October 2017
Bulletin from extraordinary
general meeting in Enzymatica AB (publ)
Enzymatica held an extraordinary
general meeting today on 25 October 2017 in Lund. The general
meeting resolved upon the following:
Resolution on personnel option
program
The extraordinary general meeting resolved in accordance with the
proposal for resolution to adopt Personnel Option Program 2017/2023
II and resolution to issue directed warrants as well as approval of
transfer of warrants. Personnel Option Program 2017/2023 II
corresponds in all material respects with the terms and conditions
for Personnel Option Program 2017/2023 as resolved by the annual
general meeting on 20 April 2017 and the purpose for the
implementation of Personnel Option Program 2017/2023 II is to
enable additional employees to participate in an incentive program
on equivalent terms. The program entails that a maximum of
1,390,000 personnel options shall be offered to a by the board
elected circle of individuals between 25 October 2017 and 25
December 2017. The holders can utilize the allotted personnel
options during the period from and including 1 May 2021 to and
including 31 July 2023. Each personnel option confers a right to
acquire one new share in the company against cash consideration at
a utilization price of SEK 4.22, which corresponds to 150 percent
of the average value of the Enzymatica share on Nasdaq First North
during the period from and including 5 April 2017 to and including
19 April 2017. The personnel options shall be allotted without
consideration and cannot be transferred.
In order to enable the delivery of shares as well
as to hedge ancillary costs, primarily social security charges, a
maximum of 1,826,738 warrants shall be issued to Enzymatica's
wholly owned subsidiary Enzymatica Care AB which thereafter may be
transferred to the participants without consideration in connection
with the utilization of personnel options. The dilution effect of
the program is approximately 2 percent. The maximum dilution effect
of program 2017/2023 and program 2017/2023 II is approximately 5
percent of the company's share capital and votes.
Extended authorization of the
board to issue new shares
The general meeting resolved to extend the existing authorization
of the board to issue new shares, resolved by the annual general
meeting in 2017, as regards reasons. The reason for deviation from
the general preferential rights, in addition to enable the company
to raise new capital and to take advantage of future opportunities
to attract new long-term owners of strategic importance to the
company, as well as to finance the company's growth strategy, is
also to enable the company to acquire the remaining minority shares
in the subsidiary Zymetech ehf. by issue in kind. In other
respects, the authorization by the annual general meeting remains
unaltered.
For
more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a life science company that
develops and sells medical devices for infection-related diseases.
The products are based on a barrier technology that includes marine
enzymes. The Company's first product is ColdZyme® Mouth Spray,
which can prevent colds and reduce the duration of disease. The
product has been launched in around ten markets. The strategy is to
continue to grow by strengthening the Company's position in
existing markets and expanding into new geographic markets through
established partners. The company is headquartered in Lund and is
listed on Nasdaq First North. For more information please
visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser
Bank.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024